Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Dec 2022

Tzou Philip L, Tao Kaiming, Sahoo Malaya K, Kosakovsky Pond Sergei L, Pinsky Benjamin A, Shafer Robert W

Abstract excerpt

INTRODUCTION: Although most laboratories are capable of employing established protocols to perform full-genome SARS-CoV-2 sequencing, many are unable to assess sequence quality, select appropriate mutation-detection thresholds, or report on the potential clinical significance of mutations in the targets of antiviral therapy METHODS: We describe the technical aspects and benchmark the performance of Sierra...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Genome, Viral

Share to Mutation

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 36334368
DOI: 10.1016/j.jcv.2022.105323
PMCID: PMC9595491

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sierra SARS-CoV-2 sequence and antiviral resistance analysis program.PMID 36334368Read ↗

COVID-19 CG: Tracking SARS-CoV-2 mutations by locations and dates of interestSemantic proximity Read ↗

SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes.Semantic proximity Read ↗

From Bench to Insight: Rapid Pathogen Genomic Surveillance Workflow for SARS-CoV-2 and Emerging Pathogens.Semantic proximity Read ↗

SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?Semantic proximity Read ↗

SABRes: A tool for in silico detection of drug resistance conferring mutations in SARS-CoV-2 genomesSemantic proximity Read ↗

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysisSemantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Genetic surveillance of SARS-CoV-2 M <sup>pro</sup> reveals high sequence and structural conservation prior to the introduction of protease inhibitor PaxlovidSemantic proximity Read ↗

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated personsSemantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

Analysis of ibuzatrelvir's activity against SARS-CoV-2 circulating variants and in vitro resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.